1-3 of 3
B. Opitz
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Higher Incidence of Secondary AML and Adverse Molecular Markers, Together with Lower CR and Higher AML Related Death Rates in Elderly Compared to Younger Patients: Results from 2435 Patients Included in the Two German AML Intergroup Studies

Dietger Niederwieser, MD, Verena Sophia Hoffmann, Dr., Utz Krug, MD, Rainer Krahl, PhD, Christina Sauerland, Dipl.-Math, Karsten Spiekermann, MD, Stefan K. Bohlander, MD, Ute Hegenbart, MD, Wolfram Poenisch, MD, Vladan Vucinic, MD, Michael Cross, PhD, Nadja Jaekel, MD, Markus Pfirrmann, Antje Schulze, Alwin Kraemer, MD, Georg Maschmeyer, MD, Christian Junghanss, MD, Sebastian Scholl, Christian Jakob, MD, Thomas Heinicke, MD, Detlev Haehling, Norma Peter, MD, Ute Kreibich, Prof., Christoph Busemann, MD, Haifa Kathrin Al-Ali, MD, Ahmet H. Elmaagacli, MD PhD, B Opitz, Hans-Heinrich Wolf, MD, Wolfgang Hiddemann, MD, Wolfgang E Berdel, MD, Thomas Buechner
Journal: Blood
Blood (2015) 126 (23): 2517.
https://doi.org/10.1182/blood.V126.23.2517.2517
Published: 2015
Journal Articles

High CR-Rate after Intensive Chemotherapy but Disappointing Results after Palliative Treatment in Patients with Acute Myeloid Leukemia Above the Age of 60 Years: An Analysis of the AML97#38 Study of the East German Hematology and Oncology Study Group (OSHO).

Cornelia Becker, R. Krahl, H.K. Al Ali, W. Poenisch, M. Cross, S. Heyn, A. Gerhardt, A. Schulze, U. Mahlknecht, D. Haehling, M. Schulze, M. Freund, E. Kettner, G. Doelken, H.H. Wolf, E. Zschuppe, N. Peter, A. Franke, U. Wedding, L. Uharek, U. Kreibich, A. Florschuetz, B. Opitz, N. Zojer, W. Helbig, Dietger Niederwieser
Journal: Blood
Blood (2007) 110 (11): 1854.
https://doi.org/10.1182/blood.V110.11.1854.1854
Published: 2007
Journal Articles

Cytogenetics and De Novo/Secondary AML but Not Age Are the Main Determinants for CR Rate and Hematological Recovery in Acute Myeloid Leukemia (AML) Using Intermediate Doses of Cytarabine (AraC) Delivered at the Presumptive Saturating Infusion Rate.

Cornelia Becker, MD, Haifa Al Ali, MD, Rainer Krahl, PhD, Wolfram Poenisch, MD, Dirk Hasenclever, PhD, Luisa Mantovani, MD, Mathias Freund, MD, R. Subert, MD, Ute Hegenbart, MD, Ulrich Wedding, MD, Johannes Meran, MD, Michael Herold, MD, Norma Peter, MD, W. Knauf, MD, Erika Kettner, MD, T. Ittel, MD, Astrid Franke, MD, K. Dachselt, MD, H.H. Wolf, MD, Ute Kreibich, MD, Manfred Schulze, MD, Michael Assmann, MD, Norbert Grobe, MD, Renate Huhn, MD, Ernst Zschuppe, MD, Veronika Schirmer, MD, U. Haak, MD, C. Klinkenstein, MD, B. Opitz, MD, Rita Pasold, MD, F. Fiedler, MD, C. Winkelmann, MD, Werner Helbig, MD, Dietger Niederwieser, MD
Journal: Blood
Blood (2005) 106 (11): 1851.
https://doi.org/10.1182/blood.V106.11.1851.1851
Published: 2005